

15 April 2026

ADOA PROGRAM: SAFETY REVIEW COMMITTEE APPROVE PROGRESSION TO MULTI-DOSE STUDY

- **PYC is progressing an investigational drug candidate (known as PYC-001) that addresses the underlying cause of a blinding eye disease called Autosomal Dominant Optic Atrophy (ADOA) through clinical trials**
- **The Company today announces that the Safety Review Committee (SRC) governing the Phase 1 Single Ascending Dose (SAD) study of PYC-001 has reviewed the 4-week safety/tolerability outcomes for ADOA patients treated with a 60 microgram dose of PYC-001 and approved progression to a multiple dose study at this dose¹**
- **PYC will now add evaluation of the safety and efficacy profile of repeat doses of 60 micrograms of PYC-001 (alongside the existing 10 and 30 microgram cohorts) in the ongoing Phase 1/2 Multiple Ascending Dose (MAD) study² of this drug candidate in patients with ADOA**
- **Data from this ongoing Phase 1/2 MAD study will be presented throughout 2026 and 2027**

PERTH, Australia and SAN FRANCISCO, California – 15 April 2026

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.

The Company currently has three clinical-stage drug development programs including an investigational drug candidate (known as PYC-001) that addresses the underlying cause of a blinding eye disease called Autosomal Dominant Optic Atrophy (ADOA). ADOA affects 1 in every 35,000³ people and there are currently no approved treatment options available for patients with ADOA.

PYC today announces that the Safety Review Committee (SRC) monitoring the Phase 1 Single Ascending Dose (SAD) study of PYC-001 in ADOA patients has reviewed the 4-week safety/tolerability data for patients dosed with 60 micrograms of PYC-001 and approved progression of this dose into a Multiple Ascending Dose (MAD) study.

¹ Through 4 weeks of follow up

² Subject to the risks and uncertainties outlined in the Company's ASX filings of 2 February 2026 including receiving regulatory and human ethics approval to do so

³ Yu-Wai-Man, P. et al. The Prevalence and Natural History of Dominant Optic Atrophy Due to OPA1 Mutations Ophthalmology. 2010;117(8):1538-46 doi: 10.1016/j.ophtha.2009.12.038

Figure 1. Overview of the Phase 1 study for PYC-001 in ADOA⁴





Figure 2. Proposed clinical development pathway for PYC-001 in ADOA⁵



Next Steps

PYC is now evaluating the safety and efficacy profile of repeat doses of PYC-001 in a global Multiple Ascending Dose (MAD) study of PYC-001 in patients with ADOA. The objective of this study is to establish clinical proof-of-concept prior to progression of the drug candidate into a global registrational trial directed towards supporting a New Drug Application for PYC-001 in ADOA. Safety and efficacy outcomes from this study will be presented throughout 2026 and 2027.

⁴ Additional details on PYC's Phase 1 study of PYC-001 in ADOA available using the clinical trials identifier: NCT06970106

⁵ Subject to regulatory approval

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development⁶.

For more information, visit pyctx.com, or follow us on [LinkedIn](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACT US

Investor relations and media contact
investor@pyctx.com



⁶ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>